Corticosteroid

In a new study, school-aged children in Scotland with uncontrolled asthma had a 3 to 6 times higher risk for COVID-19 hospitalization compared with those without asthma, researchers reported in The Lancet Respiratory Medicine.

Among patients with Crohn’s disease, achieving a sustained clinical remission off steroids with complete endoscopic remission did not correlate with less disease progression, according to study results.

Patients with nasal polyps often have a slow, frustrating path to therapy. Symptoms initially manifest as congestion or a runny nose, which may be attributed to allergies and treated with over-the-counter medications.

An individualized, biomarker-guided approach to corticosteroid dosing utilizing C-reactive protein for COVID-19-related pneumonia reduced patients’ cumulative steroid exposure and increased the number of hospital- and oxygen-free days.

The FDA recently approved Cortrophin Gel for the treatment of rheumatoid arthritis, multiple sclerosis and other autoimmune diseases. It was the top story in rheumatology last week.

The FDA has approved a supplemental new drug application for ANI Pharmaceutical’s Cortrophin Gel to treat rheumatoid arthritis, multiple sclerosis and certain other autoimmune diseases, according to a company press release.

LAS VEGAS – A humoral immune response after competition of COVID-19 vaccine series is detected in most patients with inflammatory bowel disease, including those on immunosuppressants, according to a presentation at the ACG Scientific Annual Meeting.

Compared with adult patients who more frequently experienced delayed eosinophilic esophagitis diagnosis, pediatric patients had higher endoscopic findings of the disease with increased eosinophils detected during esophageal biopsy.

This week, use of systemic corticosteroids is linked with worse COVID-19 outcomes; an investigational antiviral drug reduces risk for hospitalization and death by about 50% in patients with COVID-19; Pfizer-BioNTech submit vaccine data for children aged 5 to 11 to FDA; and more.

Patient education and treatment can safely reduce the risks that women with asthma and other allergic diseases face during pregnancy, according to a review published in Allergy.